Apnimed, Inc.(APMD)

Biotechnology · Cambridge, MA

$21.75+0.24 (+1.12%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T12:45:25.386Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:45:25.386Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA: N/A
Quote market capitalization: 866,154,230
Total debt: N/A
Cash: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

APMD EBITDA Yield Metrics

EBITDA YIELD

N/A

APMD Competitors' EBITDA Yield

APMD

Apnimed, Inc.

Current

Market Cap

$866.15M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GLUE

Monte Rosa Therapeutics, Inc.

vs APMD

Market Cap

$867.60M

EBITDA Yield

N/A

TTM Avg

3.15%

3Y Avg

3.15%

5Y Avg

3.15%

BBNX

Beta Bionics, Inc.

vs APMD

Market Cap

$852.55M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALMS

Alumis Inc.

vs APMD

Market Cap

$844.28M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ARDX

Ardelyx, Inc.

vs APMD

Market Cap

$837.43M

EBITDA Yield

N/A

TTM Avg

123.97%

3Y Avg

123.97%

5Y Avg

123.97%

CRVS

Corvus Pharmaceuticals, Inc.

vs APMD

Market Cap

$903.13M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GYRE

Gyre Therapeutics, Inc.

vs APMD

Market Cap

$819.44M

EBITDA Yield

N/A

TTM Avg

1.34%

3Y Avg

2.25%

5Y Avg

2.25%

BVS

Bioventus Inc.

vs APMD

Market Cap

$915.95M

EBITDA Yield

9.31%

TTM Avg

10.83%

3Y Avg

7.54%

5Y Avg

6.58%

HSTM

HealthStream, Inc.

vs APMD

Market Cap

$921.45M

EBITDA Yield

7.91%

TTM Avg

9.57%

3Y Avg

8.00%

5Y Avg

7.50%

ABUS

Arbutus Biopharma Corp

vs APMD

Market Cap

$922.50M

EBITDA Yield

16.24%

TTM Avg

17.01%

3Y Avg

17.01%

5Y Avg

17.01%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Apnimed, Inc. (APMD)	$866.15M	N/A	N/A	N/A	N/A
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$867.60M	N/A	3.15%	3.15%	3.15%
Beta Bionics, Inc. (BBNX)vs ›	$852.55M	N/A	N/A	N/A	N/A
Alumis Inc. (ALMS)vs ›	$844.28M	N/A	N/A	N/A	N/A
Ardelyx, Inc. (ARDX)vs ›	$837.43M	N/A	123.97%	123.97%	123.97%
Corvus Pharmaceuticals, Inc. (CRVS)vs ›	$903.13M	N/A	N/A	N/A	N/A
Gyre Therapeutics, Inc. (GYRE)vs ›	$819.44M	N/A	1.34%	2.25%	2.25%
Bioventus Inc. (BVS)vs ›	$915.95M	9.31%	10.83%	7.54%	6.58%
HealthStream, Inc. (HSTM)vs ›	$921.45M	7.91%	9.57%	8.00%	7.50%
Arbutus Biopharma Corp (ABUS)vs ›	$922.50M	16.24%	17.01%	17.01%	17.01%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

APMD EBITDA Yield Metrics

APMD Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics